JW Pharmaceutical

Quick facts

Marketed products

• Anagliptin BID Treatment · Diabetes
  Anagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.
• Placebo (for Pitavastatin)
  Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
• recomon (Epoetin Beta) · Hematology
  Recomon is a recombinant erythropoietin (EPO) that stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.
• VA · Infectious Diseases
  Valacyclovir is an antiviral medication that works by inhibiting viral DNA synthesis.
• venoferrum(iron sucrose) · Hematology
  Iron sucrose provides bioavailable iron to replenish depleted iron stores and support hemoglobin synthesis in patients with iron deficiency anemia.

Phase 3 pipeline

• C2402 · Diabetes
  C2402 is a small molecule that targets the SGLT2 receptor.
• Extension Period(JW0201) · Ophthalmology
  Extension Period (JW0201) is a drug that extends the duration of action of a biologic.
• JTZ-951 · Cardiovascular
  JTZ-951 is a selective antagonist of the apelin receptor (APJ) that modulates cardiovascular and metabolic pathways.
• JW0104+C2402
  JW0104+C2402's mechanism of action is not publicly available.
• JW0104+C2403 · Oncology
  JW0104+C2403 is a combination therapy designed to enhance anti-tumor immunity through dual mechanism targeting.
• JW0108 + C2407 · Oncology
  JW0108 + C2407 is a combination therapy designed to enhance anti-tumor immunity through dual immunological mechanisms.
• JW0201 · Diabetes
  JW0201 is a small molecule that targets the SGLT2 receptor.
• KLH-2109 Placebo + Leurprorelin acetate · Oncology
  Leuprorelin acetate is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.
• Livalo, Ezetrol · Cardiovascular
  Livalo (pitavastatin) is an HMG-CoA reductase inhibitor that lowers cholesterol by blocking the enzyme responsible for cholesterol synthesis, while Ezetrol (ezetimibe) inhibits cholesterol absorption in the intestine.
• LivaloV · Cardiovascular
  LivaloV is a statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.
• LivaloVA · Cardiovascular
  LivaloVA is a pitavastatin analog designed to lower cholesterol by inhibiting HMG-CoA reductase with enhanced potency and cardiovascular benefits.
• Placebo of Anagliptin
  A placebo does not have an active pharmacological mechanism; it is used as a control in clinical trials.
• Treatment Period(JW0201)
  JW0201 is a treatment for Treatment Period, but exact mechanism is unknown.
• Treatment Period(Placebo) · Diabetes
  This drug works by inhibiting the activity of a specific enzyme.

Phase 2 pipeline

• LEO 152020 Tablet
• URC102

Phase 1 pipeline

• C2406
• Epaminurad, Naproxen
• JW2286
• Livalo® fixed combination drug
• mitiglinide and metformin
• Phase 1a: CWP232291
• Phase 1b: CWP232291, Lenalidomide, Dexamethasone
• Pitavastatin, Valsartan
• Reference Drug or Test Drug
• Treatment A_Period 3
• Treatment B: JW0107 1 tablet

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• JW Pharmaceutical portfolio CI brief
• JW Pharmaceutical pipeline updates RSS